Advertisement

Archives of Pharmacal Research

, 29:768 | Cite as

Acanthopanax senticosus reverses fatty liver disease and hyperglycemia in ob/ob mice

  • Sang Hyun Park
  • Sang Gil Lee
  • Sung Keel Kang
  • Sung Hyun ChungEmail author
Articles Drug Development

Abstract

Non-alcoholic fatty liver disease (NAFLD) is common in obesity. However, weight reduction alone does not prevent the progression of NAFLD to end-stage disease associated with the development of cirrhosis and liver disease. In a previous experiment, 50% ethanol extract ofAcanthopanax senticosus stem bark (ASSB) was found to reduce body weight and insulin resistance in high fat diet-induced hyperglycemic and hyperlipidemic ICR mice. To evaluate the anti-steatosis action of ASSB, insulin-resistant ob/ob mice with fatty livers were treated with ASSB ethanol extract for an 8 week-period. ASSB ethanol extract reversed the hepatomegaly, as evident in reduction of % liver weight/body weight ratio. ASSB ethanol extract also specifically lowered circulating glucose and lipids, and enhanced insulin action in the liver. These changes culminated in inhibition of triglyceride synthesis in non-adipose tissues including liver and skeletal muscle. Gene expression studies confirmed reductions in glucose 6-phosphatase and lipogenic enzymes in the liver. These results demonstrate that ASSB ethanol extract is an effective treatment for insulin resistance and hepatic steatosis in ob/ob mice by decreasing hepatic lipid synthesis.

Key words

Acanthopanax senticosus stem bark Non-alcoholic fatty liver disease Insulin resistance Lipogenic enzymes Glucose 6-phosphatase 

References

  1. Angulo, P. Nonalcoholic fatty liver disease.New Engl. J. Med., 346, 1221–1231 (2002).PubMedCrossRefGoogle Scholar
  2. Chomczynski, P. and Sacchi, N., Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.Anal. Biochem. 162, 156–159 (1987).PubMedCrossRefGoogle Scholar
  3. Cohen, P., Miyazaki, M., Socci, N. D., Hagge-Greenberg, A., Liedtke, W., Soukas, A. A., Sharma, R., Hudgins, L. C., Ntambi, J. M., and Friedman, J. M., Role for stearoyl-CoA desaturase-1 in leptin-mediated weight loss.Science, 297, 240–243 (2002).PubMedCrossRefGoogle Scholar
  4. Cohen, P., Zhao, C., Cai, X., Montez, J. M., Rohani, S. C., Feinstein, P., Mombaerts, P., and Friedman, J. M., Selective deletion of leptin receptor in neurons leads to obesity.J. Clin. Invest., 108, 1113–1121 (2001).PubMedGoogle Scholar
  5. Cusi, K., Consol, A., and DeFronzo, R. A., Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.J. Clin. Endocr. and Metab. 81, 4059–4067 (1996).CrossRefGoogle Scholar
  6. Davies, G. F., Khandelwal, R. L., Wu, L., Juurlink, B. H., and Roesler, W. J., Inhibition of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by troglitazone: a peroxisome proliferator-activated receptor-gamma (PPARgamma)-independent, antioxidant-related mechanism.Biochem Pharmacol., 62, 1071–1079 (2001).PubMedCrossRefGoogle Scholar
  7. Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., and Parks, E. J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with NAFLD.J. Clin. Invest., 115, 1343–1351 (2005).PubMedGoogle Scholar
  8. Hookman, P. and Barkin, J. S., Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.Am. J. Gastroenterol., 98, 2093–2097 (2002).Google Scholar
  9. Liang, C. P. and Tall, A. R., Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver.J. Biol. Chem., 276, 49066–49076 (2001).PubMedCrossRefGoogle Scholar
  10. Lin, H. Z., Yang, S. Q., Kujhada, F., Ronnet, G., and Diehl, A. M., Metformin reverses nonalcoholic fatty liver disease in obese leptin-deficient mice.Nat. Med., 6, 998–1003 (2000).PubMedCrossRefGoogle Scholar
  11. Manco, M., Calvani, M., and Mingrone, G., Effects of dietary fatty acids on insulin sensitivity and secretion.Diabetes. Obes. Metab., 6, 402–413 (2004).PubMedCrossRefGoogle Scholar
  12. Marchesini, G., Brizi, M., Bianchi, G., Tomassetti, S., Zoli, M., and Melchionda, N., Metformin in non-alcoholic steatohepatitis.Lancet., 358, 893–894 (2001).PubMedCrossRefGoogle Scholar
  13. Matthews, D. R., Hosker, J. P., Rudenky, A. S., Naylor, B. A., Treacher, D. F., and Turner, R. C., Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man.Diabetologia, 28, 412–419 (1985).PubMedCrossRefGoogle Scholar
  14. Mithieux, G., New knowledge regarding glucose-6-phosphatase gene and protein and their roles in the regulation of glucose metabolism.Eur. J. Endocr., 136, 137–145 (1997).CrossRefGoogle Scholar
  15. Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., and Bacon, B. R., Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.Hepatology, 38, 1008–1017 (2003).PubMedGoogle Scholar
  16. Nishioka, S., Kinoshita, H., Takeda, H., and Okano, G., Phenolic compounds from the stem bark of Acanthopanax senticosus and their pharmacological effect in chronic swimming stressed rats.Chem. Pharm Bull., 38, 1763–1765 (1990).Google Scholar
  17. Schwarz, J. M., Linfoot, P., Date, D. and Aghajanian, K., Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high fat, low carbohydrate and low fat, high catbohydrate isoenergetic diets.Am. J. Clin. Nutr., 77, 43–50 (2003).PubMedGoogle Scholar
  18. Shimomura, I., Bashmakov, Y., and Horton, J. D., Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus.J. Biol. Chem. 274, 30028–30032 (1999).PubMedCrossRefGoogle Scholar
  19. Trinder, P., Determination of blood glucose using an oxidaseperoxidase system with a non-carcinogenic chromogen.J. Clin. Pathol., 22, 158–161 (1969).PubMedCrossRefGoogle Scholar
  20. Tolman, K. G., Fonseca, V., Tan, M. H., and Dalpiaz, A., Narative review: hepatobiliary disease in type 2 diabetes mellitus.Annu. Intern. Med., 141, 946–956 (2004).Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 2006

Authors and Affiliations

  • Sang Hyun Park
    • 2
  • Sang Gil Lee
    • 1
  • Sung Keel Kang
    • 1
  • Sung Hyun Chung
    • 2
    Email author
  1. 1.College of Oriental MedicineKyung Hee UniversitySeoulKorea
  2. 2.Department of Pharmacology and Clinical Pharmacy, College of PharmacyKyung Hee UniversitySeoulKorea

Personalised recommendations